Skip to main content
. 2017 Sep 7;2(17):e90874. doi: 10.1172/jci.insight.90874

Figure 6. Pretreatment with intermittent PTH reduces MDA-MB-231 human breast cancer cell engraftment in bone.

Figure 6

(A) Intratibial injection experimental design. Mice were 6 weeks of age at the start of the experiment and 10 weeks at the time of 4T1 cell injection. (B) Representative end point BLI images of hind limbs injected with MDA-MB-231 human breast cancer cells. After 4 weeks, tumors were identified in 5 of 15 PTH-treated mice compared with 11 of 15 PBS-treated mice (P = 0.027, by 1-way ANOVA with Bonferroni’s test as post-hoc analysis). (C) Quantitation of BLI 4 weeks after intratibial injections of MDA cells. All values represent mean ± SD of n = 15 for each group. *P < 0.05, when compared with PBS group, by 1-way ANOVA with Bonferroni’s test as post-hoc analysis.